US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Seven sneaky clauses in estate agent contracts that can cost you dear
When it comes to picking an estate agent, for most people their mind is made up long before the cont2024-05-22- Chinese Foreign Minister Wang Yi, also a member of the Political Bureau of the Communist Party of Ch2024-05-22
Songs of celebration hail anniversary
The Forbidden City Concert Hall has announced a series of programs to mark the 25th anniversary of t2024-05-22China's NEVs powering up to lead global sustainability charge
People visit the 2024 Beijing International Automotive Exhibition in Shunyi District, Beijing, capit2024-05-22Nigella Lawson, 64, reveals she would 'never take Ozempic' as a weight
It's ability to suppress appetite, cut alcohol cravings and accelerate weight loss means its use in2024-05-228th Aswan int'l women film festival opens in Egypt
The eighth edition of the Aswan International Women Film Festival (AIWFF) opens Saturday night in Eg2024-05-22
atest comment